Cargando…

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Rosell, Rafael, Karachaliou, Niki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085495/ https://www.ncbi.nlm.nih.gov/pubmed/29929887 http://dx.doi.org/10.1016/j.ebiom.2018.06.007

Ejemplares similares

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Expression Profiles and Clinicopathologic Features in Early Resected Non-small-cell Lung Cancer()
por: Rosell, Rafael
Publicado: (2014)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening
por: Rosell, Rafael, et al.
Publicado: (2015)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Rhomboids and regulation of receptor tyrosine kinase ligands shedding
por: Karachaliou, Niki, et al.
Publicado: (2018)

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy
por: Rosell, Rafael, et al.
Publicado: (2019)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
por: Van Laar, Ryan K
Publicado: (2012)

Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2020)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges
por: Karachaliou, Niki, et al.
Publicado: (2018)

Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer
por: Liu, Yu, et al.
Publicado: (2021)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
por: Lazzari, Chiara, et al.
Publicado: (2018)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy
por: Zeng, Yuan, et al.
Publicado: (2021)

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
por: Qi, Lishuang, et al.
Publicado: (2016)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma
por: Xie, Dong, et al.
Publicado: (2020)

A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
por: Wang, Xiangxue, et al.
Publicado: (2021)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Advances in immunotherapy for treatment of lung cancer
por: Bustamante Alvarez, Jean G., et al.
Publicado: (2015)

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kuapvf74i2m6epqk2i13thrpqv